Our mission is to deliver solutions and bring hope to as many people as possible.

Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcare systems worldwide.

More info

Growth driven by passion and commitment, enabling us to enter any market and adapt to challenges with dedication and talent.

More info

Trust built on the values and the experience of a dynamic, multi-disciplinary and highly qualified team.

The application of a unified work methodology, with a focus on quality in everything we do.

More info

 

Our mission is to deliver solutions and bring hope to as many people as possible.

Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcare systems worldwide.

More info

 

Growth driven by passion and commitment, enabling us to enter any market and adapt to challenges with dedication and talent.

More info

 

Trust built on the values and the experience of a dynamic, multi-disciplinary and highly qualified team.

The application of a unified work methodology, with a focus on quality in everything we do.

More info

ABOUT
mAbxience

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

mAbxience is a fully integrated biopharmaceutical company specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.

Partnerships

mAbxience has successfully established alliances around the world with key partners, allowing patients access to our quality products across the globe.

We work to ensure supply of affordable medicines to health care systems worldwide, adapting to the needs of each regulatory and commercial environment.

mAbNews

PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccines

09/22/2021

Washington DC, September 21, 2021 (PAHO) – The Pan American Health Organization (PAHO) has announced the selection of two centers in Argentina and Brazil as regional hubs for the development and production of mRNA-based vaccines in Latin America in a bid to tackle COVID-19 and future infectious-disease challenges. The Bio-Manguinhos Institute of Technology on Immunobiologicals […]

Insud Pharma secures “Excellent” rating in the Profarma programme

05/05/2021

It is a recognition of the brands of the group Chemo, Exeltis and mAbxience for their commitment to industrial development and investment in our country It is the second consecutive year that the group has received this rating from the Ministry of Industry The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and […]

European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer

03/31/2021

The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.

mAbxience is a Spanish fully-fledged biotech company with a decade of experience in developing and manufacturing biosimilars.

Part of the Spanish multinational Insud Pharma (formerly Chemo), a group with +40 years of experience, more than 6,000 professionals and presence in 40 countries around the world.

Bio-Europe Spring 2021

Meet us at Bio-Europe Spring, to be held 22-25 March. 2021.

+

Our business model is B2B (business to business), with global partnership network of key market leaders in the EU, US, Japan and emerging markets.

+